Haplo?identical or mismatched unrelated donor hematopoietic cell transplantation for <scp>Fanconi</scp> anemia: Results from the <scp>Severe Aplastic Anemia Working Party</scp> of the <scp>EBMT</scp>

Allogeneic hematopoietic cell transplantation (HCT) is the only curative option for bone marrow failure or malignant diseases Fanconi anemia (FA) patients. Although results have improved over last decades, reaching more than 90% survival when a human leukocyte antigen (HLA)-identical donor available, alternative HCT donors are still less reported. We compared outcomes using HLA-mismatched unrelated (MMUD; n = 123) haplo-identical (HDs), either in vivo T depletion (n 33) cells depleted with some type of graft manipulation ex 59) performed FA between 2000 and 2018. Overall (OS) by 24 months was 62% (53–71%) MMUD, versus 80% (66–95%) HDs 60% (47–73%) (p .22). Event-free (EFS) better HD-transplanted patients 86% (73–99%) those transplanted from MMUD 58% (48–68%) 56% (42–69%) .046). Grade II-IV acute graft-versus-host disease (GVHD) 41% (MMUD) 40% (HDs no manipulation) 17% graft), .005). No differences were found other transplant related outcomes. These data suggest that might be considered as an EFS unmanipulated grafts.